NO328527B1 - Ny anvendelse av docetaxel for behandling av hepatoma - Google Patents

Ny anvendelse av docetaxel for behandling av hepatoma Download PDF

Info

Publication number: NO328527B1
Authority: NO; Norway
Prior art keywords: docetaxel; cells; treatment; paclitaxel; hours
Prior art date: 1999-08-31

Application number

NO20020829A

Other languages

English (en)

Norwegian (no)

Other versions

NO20020829L (no

NO20020829D0 (no

Inventor

Chin-Wen Chi

Heng-Liang Lin

Tsung-Yun Liu

Wing-Yiu Liu

Gar-Yang Chau

Original Assignee

Aventis Pharma Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-08-31

Filing date

2002-02-20

Publication date

2010-03-08

2002-02-20 Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa

2002-02-20 Publication of NO20020829L publication Critical patent/NO20020829L/no

2002-02-20 Publication of NO20020829D0 publication Critical patent/NO20020829D0/no

2010-03-08 Publication of NO328527B1 publication Critical patent/NO328527B1/no

Links

229960003668 docetaxel Drugs 0.000 title claims abstract description 70
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 title claims abstract description 67
206010073071 hepatocellular carcinoma Diseases 0.000 title claims abstract description 29
231100000844 hepatocellular carcinoma Toxicity 0.000 claims abstract description 22
238000002360 preparation method Methods 0.000 claims description 18
238000001802 infusion Methods 0.000 claims description 8
239000000825 pharmaceutical preparation Substances 0.000 claims description 7
150000001875 compounds Chemical class 0.000 claims description 5
238000001990 intravenous administration Methods 0.000 claims description 3
238000007911 parenteral administration Methods 0.000 claims description 3
150000004684 trihydrates Chemical class 0.000 claims description 3
239000004480 active ingredient Substances 0.000 claims 1
238000007918 intramuscular administration Methods 0.000 claims 1
238000007912 intraperitoneal administration Methods 0.000 claims 1
238000007916 intrasternal administration Methods 0.000 claims 1
238000007920 subcutaneous administration Methods 0.000 claims 1
229930012538 Paclitaxel Natural products 0.000 abstract description 37
229960001592 paclitaxel Drugs 0.000 abstract description 37
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract description 37
239000003814 drug Substances 0.000 abstract description 4
238000004519 manufacturing process Methods 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 58
-1 Docetaxel hydrates Chemical class 0.000 description 11
239000000243 solution Substances 0.000 description 10
238000000034 method Methods 0.000 description 8
XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 8
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
239000007864 aqueous solution Substances 0.000 description 6
238000000684 flow cytometry Methods 0.000 description 6
230000035899 viability Effects 0.000 description 6
230000001640 apoptogenic effect Effects 0.000 description 5
230000022131 cell cycle Effects 0.000 description 5
230000003833 cell viability Effects 0.000 description 5
239000012528 membrane Substances 0.000 description 5
239000000047 product Substances 0.000 description 5
206010028980 Neoplasm Diseases 0.000 description 4
XCDIRYDKECHIPE-QHEQPUDQSA-N docetaxel trihydrate Chemical compound O.O.O.O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 XCDIRYDKECHIPE-QHEQPUDQSA-N 0.000 description 4
230000007717 exclusion Effects 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
238000013467 fragmentation Methods 0.000 description 4
238000006062 fragmentation reaction Methods 0.000 description 4
239000002609 medium Substances 0.000 description 4
239000008188 pellet Substances 0.000 description 4
230000035699 permeability Effects 0.000 description 4
239000004094 surface-active agent Substances 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
230000037059 G2/M phase arrest Effects 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
238000003556 assay Methods 0.000 description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
231100000433 cytotoxic Toxicity 0.000 description 3
230000001472 cytotoxic effect Effects 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
229940079593 drug Drugs 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000012139 lysis buffer Substances 0.000 description 3
230000009467 reduction Effects 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
210000004881 tumor cell Anatomy 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
CQOQDQWUFQDJMK-SSTWWWIQSA-N 2-methoxy-17beta-estradiol Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CCC1=C2C=C(OC)C(O)=C1 CQOQDQWUFQDJMK-SSTWWWIQSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
230000004668 G2/M phase Effects 0.000 description 2
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
239000007900 aqueous suspension Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
230000000875 corresponding effect Effects 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
229950010692 docetaxel trihydrate Drugs 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
229960005420 etoposide Drugs 0.000 description 2
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
239000012737 fresh medium Substances 0.000 description 2
239000008103 glucose Substances 0.000 description 2
239000000367 immunologic factor Substances 0.000 description 2
238000011534 incubation Methods 0.000 description 2
229960000485 methotrexate Drugs 0.000 description 2
239000000203 mixture Substances 0.000 description 2
239000012457 nonaqueous media Substances 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
230000008569 process Effects 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
VOXBZHOHGGBLCQ-UHFFFAOYSA-N 2-amino-3,7-dihydropurine-6-thione;hydrate Chemical compound O.N1C(N)=NC(=S)C2=C1N=CN2.N1C(N)=NC(=S)C2=C1N=CN2 VOXBZHOHGGBLCQ-UHFFFAOYSA-N 0.000 description 1
NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
239000005695 Ammonium acetate Substances 0.000 description 1
108010024976 Asparaginase Proteins 0.000 description 1
206010003645 Atopy Diseases 0.000 description 1
108010006654 Bleomycin Proteins 0.000 description 1
208000003174 Brain Neoplasms Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
GTEBGKZZGCBLNT-RVWNTZLHSA-N CC(O)=O.C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(OC)[C@H](C(C)=O)[C@@]1(C)CC2 Chemical compound CC(O)=O.C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(OC)[C@H](C(C)=O)[C@@]1(C)CC2 GTEBGKZZGCBLNT-RVWNTZLHSA-N 0.000 description 1
FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 1
DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
108010092160 Dactinomycin Proteins 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
108010067770 Endopeptidase K Proteins 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229930192392 Mitomycin Natural products 0.000 description 1
206010027761 Mixed hepatocellular cholangiocarcinoma Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
241001116498 Taxus baccata Species 0.000 description 1
PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
229940122803 Vinca alkaloid Drugs 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
230000001780 adrenocortical effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
150000008052 alkyl sulfonates Chemical class 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
229960003437 aminoglutethimide Drugs 0.000 description 1
ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
229940043376 ammonium acetate Drugs 0.000 description 1
235000019257 ammonium acetate Nutrition 0.000 description 1
239000003098 androgen Substances 0.000 description 1
229940030486 androgens Drugs 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
229940046836 anti-estrogen Drugs 0.000 description 1
230000001833 anti-estrogenic effect Effects 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
229940045686 antimetabolites antineoplastic purine analogs Drugs 0.000 description 1
229940045687 antimetabolites folic acid analogs Drugs 0.000 description 1
239000003080 antimitotic agent Substances 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
229940045688 antineoplastic antimetabolites pyrimidine analogues Drugs 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
230000000712 assembly Effects 0.000 description 1
238000000429 assembly Methods 0.000 description 1
238000002306 biochemical method Methods 0.000 description 1
229960001561 bleomycin Drugs 0.000 description 1
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
239000004067 bulking agent Substances 0.000 description 1
229960002092 busulfan Drugs 0.000 description 1
235000013877 carbamide Nutrition 0.000 description 1
229960005243 carmustine Drugs 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
230000025084 cell cycle arrest Effects 0.000 description 1
230000006369 cell cycle progression Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
229960004630 chlorambucil Drugs 0.000 description 1
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
208000011588 combined hepatocellular carcinoma and cholangiocarcinoma Diseases 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
229960000684 cytarabine Drugs 0.000 description 1
229960003901 dacarbazine Drugs 0.000 description 1
229960000640 dactinomycin Drugs 0.000 description 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
229960000975 daunorubicin Drugs 0.000 description 1
230000034994 death Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
230000029087 digestion Effects 0.000 description 1
150000004683 dihydrates Chemical class 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000012154 double-distilled water Substances 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000002275 effect on microtubule Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
239000000328 estrogen antagonist Substances 0.000 description 1
238000012869 ethanol precipitation Methods 0.000 description 1
229960002568 ethinylestradiol Drugs 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
201000004098 fibrolamellar carcinoma Diseases 0.000 description 1
238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
229960001751 fluoxymesterone Drugs 0.000 description 1
YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
150000002224 folic acids Chemical class 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
229950000801 hydroxyprogesterone caproate Drugs 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229960002247 lomustine Drugs 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
201000010893 malignant breast melanoma Diseases 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229960004961 mechlorethamine Drugs 0.000 description 1
HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
229960004296 megestrol acetate Drugs 0.000 description 1
229960001924 melphalan Drugs 0.000 description 1
SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
229960001428 mercaptopurine Drugs 0.000 description 1
CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
229960000350 mitotane Drugs 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
150000002895 organic esters Chemical class 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
229940026778 other chemotherapeutics in atc Drugs 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
229960003171 plicamycin Drugs 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
229960004618 prednisone Drugs 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
229960000624 procarbazine Drugs 0.000 description 1
239000000583 progesterone congener Substances 0.000 description 1
150000003212 purines Chemical class 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
229960003440 semustine Drugs 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000012192 staining solution Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
229960001603 tamoxifen Drugs 0.000 description 1
229960001278 teniposide Drugs 0.000 description 1
NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
229960001712 testosterone propionate Drugs 0.000 description 1
150000004685 tetrahydrates Chemical class 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000036962 time dependent Effects 0.000 description 1
229960003087 tioguanine Drugs 0.000 description 1
150000003672 ureas Chemical class 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
229960004528 vincristine Drugs 0.000 description 1
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
229960004355 vindesine Drugs 0.000 description 1
UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
229960002066 vinorelbine Drugs 0.000 description 1
GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Gastroenterology & Hepatology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Epoxy Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)

NO20020829A 1999-08-31 2002-02-20 Ny anvendelse av docetaxel for behandling av hepatoma NO328527B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9920548.6A GB9920548D0 (en)	1999-08-31	1999-08-31	Treatment of hepatocellular carcinoma
PCT/EP2000/008782 WO2001015675A2 (en)	1999-08-31	2000-08-29	Use of docetaxel for treating hepatocellular carcinoma

Publications (3)

Publication Number	Publication Date
NO20020829L NO20020829L (no)	2002-02-20
NO20020829D0 NO20020829D0 (no)	2002-02-20
NO328527B1 true NO328527B1 (no)	2010-03-08

Family

ID=10860081

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20020829A NO328527B1 (no)	1999-08-31	2002-02-20	Ny anvendelse av docetaxel for behandling av hepatoma

Country Status (34)

Country	Link
US (2)	US20030158249A1 (cs)
EP (1)	EP1214061B1 (cs)
JP (1)	JP4866522B2 (cs)
KR (1)	KR100670416B1 (cs)
CN (1)	CN1174748C (cs)
AT (1)	ATE269700T1 (cs)
AU (1)	AU777583B2 (cs)
BG (1)	BG65913B1 (cs)
BR (1)	BR0013625A (cs)
CA (1)	CA2382294C (cs)
CZ (1)	CZ301378B6 (cs)
DE (1)	DE60011794T2 (cs)
DK (1)	DK1214061T3 (cs)
EA (1)	EA004804B1 (cs)
EE (1)	EE05124B1 (cs)
ES (1)	ES2218223T3 (cs)
GB (1)	GB9920548D0 (cs)
HK (1)	HK1048944B (cs)
HR (1)	HRP20020171A2 (cs)
HU (1)	HU228861B1 (cs)
IL (2)	IL147489A0 (cs)
ME (1)	MEP7809A (cs)
MX (1)	MXPA02002041A (cs)
NO (1)	NO328527B1 (cs)
NZ (1)	NZ517604A (cs)
PL (1)	PL212612B1 (cs)
PT (1)	PT1214061E (cs)
RS (1)	RS50148B (cs)
SI (1)	SI1214061T1 (cs)
SK (1)	SK286378B6 (cs)
TW (1)	TW589180B (cs)
UA (1)	UA72927C2 (cs)
WO (1)	WO2001015675A2 (cs)
ZA (1)	ZA200201408B (cs)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1268619C (zh)	2003-05-08	2006-08-09	上海迪赛诺化学制药有限公司	多烯紫杉醇三水化合物的制备方法
EP1694660B1 (en) *	2003-12-12	2009-04-08	Quiral Quimica Do Brasil	Process for the preparation of anhydrous and hydrated active pharmaceutical ingredients (apis); stable pharmaceutical compositions prepared from the same and uses of said compositions
US7449196B2 (en) *	2004-07-09	2008-11-11	Robert Sabin	Anti tumor compositions and methods of use
PT1931321T (pt)	2005-08-31	2019-05-14	Abraxis Bioscience Llc	Composições compreendendo agentes farmacêuticos pouco hidrossolúveis e agentes antimicrobianos
CA2620389C (en)	2005-08-31	2014-06-17	Abraxis Bioscience, Llc	Compositions and methods for preparation of poorly water soluble drugs with increased stability
US9839667B2 (en)	2005-10-14	2017-12-12	Allergan, Inc.	Prevention and treatment of ocular side effects with a cyclosporin
US20080081051A1 (en) *	2006-09-28	2008-04-03	Robert Sabin	Method of manufacturing anti-tumor and anti-viral compositions
EP2146695A4 (en) *	2007-04-23	2010-05-19	Sun Pharmaceuticals Ind Ltd	PHARMACEUTICAL COMPOSITIONS
FR2917088B1 (fr) *	2007-06-08	2009-09-04	Aventis Pharma Sa	Dissolution directe du docetaxel dans un solvant dans le polysorbate 80
US8541360B2 (en) *	2008-11-19	2013-09-24	Ben Venue Laboratories, Inc.	Parenteral formulations comprising sugar-based esters and ethers
CN104784121A (zh)	2010-03-26	2015-07-22	阿布拉科斯生物科学有限公司	治疗肝细胞癌的方法
MX341082B (es) *	2010-05-03	2016-08-08	Teikoku Pharma Usa Inc	Formulaciones de pro-emulsion de taxano no acuosas y metodos para hacer y usar las mismas.
US8842114B1 (en)	2011-04-29	2014-09-23	Nvidia Corporation	System, method, and computer program product for adjusting a depth of displayed objects within a region of a display
JO3685B1 (ar)	2012-10-01	2020-08-27	Teikoku Pharma Usa Inc	صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
EP3258913A1 (en) *	2015-02-17	2017-12-27	Mallinckrodt Nuclear Medicine LLC	Modified docetaxel liposome formulations and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2601675B1 (fr) *	1986-07-17	1988-09-23	Rhone Poulenc Sante	Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2629819B1 (fr) *	1988-04-06	1990-11-16	Rhone Poulenc Sante	Procede de preparation de derives de la baccatine iii et de la desacetyl-10 baccatine iii
US5543154A (en) *	1991-12-27	1996-08-06	Merck & Co., Inc.	Controlled release nifedipine delivery device
CA2150372C (en) *	1993-01-19	2002-08-20	Nancy L. Mills	Stable oral ci-981 formulation and process of preparing same
US5846945A (en) *	1993-02-16	1998-12-08	Onyx Pharmaceuticals, Inc.	Cytopathic viruses for therapy and prophylaxis of neoplasia
US5436243A (en) *	1993-11-17	1995-07-25	Research Triangle Institute Duke University	Aminoanthraquinone derivatives to combat multidrug resistance
FR2718963B1 (fr) *	1994-04-25	1996-05-24	Rhone Poulenc Rorer Sa	Nouvelle composition pharmaceutique à base de taxoïdes.
FR2722191B1 (fr) *	1994-07-08	1996-08-23	Rhone Poulenc Rorer Sa	Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle
US5968972A (en)	1995-10-26	1999-10-19	Baker Norton Pharmaceuticals, Inc.	Method for increasing the oral bioactivity of pharmaceutical agents
US6245805B1 (en) *	1995-10-26	2001-06-12	Baker Norton Pharmaceuticals, Inc.	Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
FR2742751B1 (fr) *	1995-12-22	1998-01-30	Rhone Poulenc Rorer Sa	Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
US6503893B2 (en) *	1996-12-30	2003-01-07	Bone Care International, Inc.	Method of treating hyperproliferative diseases using active vitamin D analogues
CA2628857C (en) *	1996-12-30	2011-09-13	Batelle Memorial Institute	Formulation and method for treating neoplasms by inhalation
EP1023050B1 (en) *	1997-06-27	2013-09-25	Abraxis BioScience, LLC	Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
AU1146099A (en) *	1997-09-18	1999-04-05	Janssen Pharmaceutica N.V.	Fused imidazole derivatives for improving oral bioavailability of pharmaceuticalagents
EP1027045A4 (en) *	1997-10-31	2004-12-08	Arch Dev Corp	METHODS AND COMPILATIONS FOR REGULATING S-ALPHA REDUCTASE ACTIVITY
UA73092C2 (uk) *	1998-07-17	2005-06-15	Брістол-Майерс Сквібб Компані	Таблетка з ентеросолюбільним покриттям і спосіб її приготування
EP1140194A2 (en) *	1998-12-23	2001-10-10	G.D. SEARLE & CO.	Use of cyclooxygenase-2 inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combined treatment of neoplasia
GB9909925D0 (en) *	1999-04-29	1999-06-30	Pharmacia & Upjohn Spa	Combined preparations comprising anthracycline derivatives
CN101370774A (zh) *	2005-12-13	2009-02-18	特瓦制药工业有限公司	阿托伐他汀半钙的晶形及其制备方法

1999
- 1999-08-31 GB GBGB9920548.6A patent/GB9920548D0/en not_active Ceased
- 1999-09-22 TW TW088115041A patent/TW589180B/zh not_active IP Right Cessation
2000
- 2000-08-29 WO PCT/EP2000/008782 patent/WO2001015675A2/en not_active Ceased
- 2000-08-29 CA CA002382294A patent/CA2382294C/en not_active Expired - Fee Related
- 2000-08-29 NZ NZ517604A patent/NZ517604A/en not_active IP Right Cessation
- 2000-08-29 IL IL14748900A patent/IL147489A0/xx active IP Right Grant
- 2000-08-29 SK SK271-2002A patent/SK286378B6/sk not_active IP Right Cessation
- 2000-08-29 DK DK00964144T patent/DK1214061T3/da active
- 2000-08-29 DE DE60011794T patent/DE60011794T2/de not_active Expired - Lifetime
- 2000-08-29 AU AU75168/00A patent/AU777583B2/en not_active Ceased
- 2000-08-29 CZ CZ20020739A patent/CZ301378B6/cs not_active IP Right Cessation
- 2000-08-29 PT PT00964144T patent/PT1214061E/pt unknown
- 2000-08-29 PL PL353198A patent/PL212612B1/pl unknown
- 2000-08-29 CN CNB008114501A patent/CN1174748C/zh not_active Expired - Fee Related
- 2000-08-29 ME MEP-78/09A patent/MEP7809A/xx unknown
- 2000-08-29 UA UA2002021546A patent/UA72927C2/uk unknown
- 2000-08-29 RS YUP-114/02A patent/RS50148B/sr unknown
- 2000-08-29 HR HR20020171A patent/HRP20020171A2/hr not_active Application Discontinuation
- 2000-08-29 HU HU0203197A patent/HU228861B1/hu not_active IP Right Cessation
- 2000-08-29 HK HK03101197.6A patent/HK1048944B/zh not_active IP Right Cessation
- 2000-08-29 KR KR1020027002446A patent/KR100670416B1/ko not_active Expired - Fee Related
- 2000-08-29 EE EEP200200087A patent/EE05124B1/xx not_active IP Right Cessation
- 2000-08-29 MX MXPA02002041A patent/MXPA02002041A/es active IP Right Grant
- 2000-08-29 ES ES00964144T patent/ES2218223T3/es not_active Expired - Lifetime
- 2000-08-29 SI SI200030478T patent/SI1214061T1/xx unknown
- 2000-08-29 EA EA200200313A patent/EA004804B1/ru not_active IP Right Cessation
- 2000-08-29 BR BR0013625-5A patent/BR0013625A/pt not_active Application Discontinuation
- 2000-08-29 JP JP2001519889A patent/JP4866522B2/ja not_active Expired - Fee Related
- 2000-08-29 AT AT00964144T patent/ATE269700T1/de active
- 2000-08-29 EP EP00964144A patent/EP1214061B1/en not_active Expired - Lifetime
2002
- 2002-01-06 IL IL147489A patent/IL147489A/en not_active IP Right Cessation
- 2002-02-19 ZA ZA200201408A patent/ZA200201408B/xx unknown
- 2002-02-20 NO NO20020829A patent/NO328527B1/no not_active IP Right Cessation
- 2002-02-27 US US10/083,565 patent/US20030158249A1/en not_active Abandoned
- 2002-02-28 BG BG106460A patent/BG65913B1/bg unknown
2007
- 2007-06-12 US US11/761,512 patent/US20080045584A1/en not_active Abandoned

Also Published As

Publication number	Publication date
KR20020060166A (ko)	2002-07-16
DE60011794T2 (de)	2005-07-14
HUP0203197A3 (en)	2005-01-28
IL147489A (en)	2006-06-11
KR100670416B1 (ko)	2007-01-17
EA200200313A1 (ru)	2002-08-29
RS50148B (sr)	2009-05-06
EP1214061A2 (en)	2002-06-19
JP4866522B2 (ja)	2012-02-01
PL353198A1 (en)	2003-11-03
CZ2002739A3 (cs)	2002-06-12
EA004804B1 (ru)	2004-08-26
ME00624B (me)	2011-12-20
CA2382294C (en)	2008-06-03
PT1214061E (pt)	2004-09-30
UA72927C2 (uk)	2005-05-16
CA2382294A1 (en)	2001-03-08
WO2001015675A3 (en)	2001-09-20
DE60011794D1 (de)	2004-07-29
SI1214061T1 (en)	2004-12-31
DK1214061T3 (da)	2004-11-01
EE05124B1 (et)	2009-02-16
EP1214061B1 (en)	2004-06-23
HUP0203197A2 (hu)	2003-01-28
CN1372466A (zh)	2002-10-02
US20080045584A1 (en)	2008-02-21
YU11402A (sh)	2005-07-19
ATE269700T1 (de)	2004-07-15
AU7516800A (en)	2001-03-26
HK1048944A1 (en)	2003-04-25
MEP7809A (en)	2011-12-20
AU777583B2 (en)	2004-10-21
GB9920548D0 (en)	1999-11-03
HRP20020171A2 (en)	2004-02-29
ES2218223T3 (es)	2004-11-16
NO20020829L (no)	2002-02-20
MXPA02002041A (es)	2002-08-20
CZ301378B6 (cs)	2010-02-03
HU228861B1 (hu)	2013-06-28
HK1048944B (zh)	2005-04-22
IL147489A0 (en)	2002-08-14
BG65913B1 (bg)	2010-05-31
WO2001015675A2 (en)	2001-03-08
CN1174748C (zh)	2004-11-10
BG106460A (bg)	2002-09-30
EE200200087A (et)	2003-04-15
SK286378B6 (sk)	2008-08-05
NZ517604A (en)	2004-04-30
ZA200201408B (en)	2003-07-30
SK2712002A3 (en)	2002-07-02
BR0013625A (pt)	2002-05-14
PL212612B1 (pl)	2012-10-31
TW589180B (en)	2004-06-01
JP2003508427A (ja)	2003-03-04
NO20020829D0 (no)	2002-02-20
US20030158249A1 (en)	2003-08-21

Publication	Publication Date	Title
US20080045584A1 (en)	2008-02-21	Use of Docetaxel for Treating Hepatocellular Carcinoma
Burke et al.	1971	Imidazole carboxamide therapy in advanced malignant melanoma
EP4331614A1 (en)	2024-03-06	Use of medicament in treatment of tumor disease
US8580847B2 (en)	2013-11-12	Antrocin containing pharmaceutical compositions for inhibiting cancer cells
KR20160141748A (ko)	2016-12-09	항암제 및 부작용 경감제
US6011041A (en)	2000-01-04	Use of anhydrovinblastine
JP6967247B1 (ja)	2021-11-17	抗マラリア剤
US20110263700A1 (en)	2011-10-27	Antrocin containing pharmaceutical compositions for inhibiting cancer cells
JPH11209283A (ja)	1999-08-03	抗癌剤
US20020103218A1 (en)	2002-08-01	Anhydrovinblastine for the treatment of cancer
CA2199065A1 (en)	1998-09-04	Anhydrovinblastine for the treatment of cancer
MXPA99008108A (en)	2000-08-01	Anhydrovinblastine for the treatment of cervical and lung cancer

Legal Events

Date	Code	Title	Description
2016-03-29	MM1K	Lapsed by not paying the annual fees